CenterBook Partners LP Increases Holdings in Intuitive Surgical, Inc. $ISRG

CenterBook Partners LP raised its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 33.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,236 shares of the medical equipment provider’s stock after acquiring an additional 1,316 shares during the period. CenterBook Partners LP’s holdings in Intuitive Surgical were worth $2,342,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of ISRG. Tobam increased its stake in Intuitive Surgical by 666.7% during the 2nd quarter. Tobam now owns 46 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 40 shares in the last quarter. Kilter Group LLC purchased a new stake in shares of Intuitive Surgical during the second quarter valued at approximately $27,000. Greykasell Wealth Strategies Inc. purchased a new stake in shares of Intuitive Surgical during the third quarter valued at approximately $27,000. Riggs Asset Managment Co. Inc. increased its position in shares of Intuitive Surgical by 84.2% during the second quarter. Riggs Asset Managment Co. Inc. now owns 70 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 32 shares in the last quarter. Finally, First Command Advisory Services Inc. raised its holdings in Intuitive Surgical by 3,750.0% in the 2nd quarter. First Command Advisory Services Inc. now owns 77 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 75 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Mark Brosius sold 464 shares of the company’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $548.49, for a total transaction of $254,499.36. Following the completion of the transaction, the senior vice president owned 131 shares in the company, valued at approximately $71,852.19. This represents a 77.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gary S. Guthart sold 2,800 shares of Intuitive Surgical stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $531.52, for a total transaction of $1,488,256.00. Following the completion of the sale, the director owned 15,720 shares in the company, valued at approximately $8,355,494.40. This represents a 15.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 56,189 shares of company stock worth $30,785,441 over the last quarter. Company insiders own 0.70% of the company’s stock.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG opened at $499.53 on Friday. The stock has a market cap of $177.40 billion, a PE ratio of 63.31, a price-to-earnings-growth ratio of 3.88 and a beta of 1.65. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $608.16. The firm has a fifty day moving average price of $536.64 and a 200-day moving average price of $510.37.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share for the quarter, topping the consensus estimate of $2.27 by $0.26. The company had revenue of $2.87 billion during the quarter, compared to the consensus estimate of $2.72 billion. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. Intuitive Surgical’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.21 EPS. On average, research analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Royal Bank Of Canada lifted their target price on Intuitive Surgical from $625.00 to $650.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. TD Cowen raised Intuitive Surgical to a “strong-buy” rating in a research report on Tuesday, January 27th. Raymond James Financial upped their target price on shares of Intuitive Surgical from $603.00 to $615.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Barclays set a $712.00 price target on shares of Intuitive Surgical and gave the stock an “overweight” rating in a research note on Monday, January 26th. Finally, Citigroup restated a “neutral” rating and set a $590.00 price objective (down previously from $635.00) on shares of Intuitive Surgical in a research report on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $617.23.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.